No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

期刊论文
出版模式：

开放获取
发表日期：

2024年2月22日

查看全文

Ahmet Yalcinkaya,
Marco Cavalli,
Axel Cederholm,
Maribel Aranda-Guillén,
Anish Behere,
Hedvig Mildner,
Tadepally Lakshmikanth,
Laura Gonzalez,
Constantin Habimana Mugabo,
Anette Johnsson,
Olov Ekwall,
Olle Kämpe,
Sophie Bensing,
Petter Brodin,
Pär Hallberg,
Mia Wadelius,
Nils Landegren

摘要

Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.